Bookmark

Add to MyYahoo RSS

Pharmaceutical News

Pharmaceuticals news continually updated from thousands of sources around the net.

4 min ago | JD Supra

Third Circuit Rejects Presumption of Irreparable Harm for Injunctive Relief under Lanham Act

Following a series of recent appellate decisions across the spectrum of intellectual property disciplines, including the fields of patent, copyright and trade secrets, the Court of Appeals for the Third Circuit has ruled that a plaintiff cannot rely on a presumption of irreparable harm in seeking preliminary injunctive relief under the Lanham Act.

Comment?

Related Topix: Patent / Trademark Law, Law, Third Circuit Court of Appeals, Biotech, Watson Pharmaceuticals, Medicine, Healthcare Industry

3 hrs ago | AmericanBankingNews.com

Cardinal Health Receives Average Rating of "Buy" from Analysts

Cardinal Health has been given an average recommendation of "Buy" by the nineteen brokerages that are currently covering the stock, American Banking News.com reports .

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Cardinal Health

7 hrs ago | Wall Street Journal

J&J, Bayer Aim to Expand Xarelto's Uses

New Trials Could Help Double the Number of Indications for the Drug, Already Poised to Beat $1 Billion in 2014 Sales Johnson & Johnson and Bayer AG announced plans Friday to launch clinical trials of the anticoagulant Xarelto against three new diseases in an ambitious bid to widen the market for a drug poised to exceed $1 billion in sales this ... (more)

Comment?

Related Topix: Manufacturing, Biotech, Bayer AG, Chemicals

11 hrs ago | Sys-Con Media

Harwood Feffer LLP Announces Investigation of Lannett Company, Inc.

Between 2013 and 2014, certain of the Company's officers and directors made statements about the Company's business concerning the sale of digoxin, a drug used for treatment of heart failure.

Comment?

Related Topix: Lannett Company, Biotech, Medicine, Healthcare Industry

15 hrs ago | Business Wire

Press release distribution, EDGAR filing, XBRL, regulatory filings

This report provides a summary of individual companies... )--Lannett Company, Inc. today announced that the company will present at the Morgan Stanley Global Healthcare Conference 2014 on Monday, September 8, 2014, ... )--Research and Markets has announced the addition of the "Market Research Report on Global and Chinese Zin... )--Fitch Ratings has ... (more)

Comment?

Related Topix: Biotech, Lannett Company, Medicine, Healthcare Industry, Solar Energy, Renewable Energy (Green Energy), Energy, Alternative Energy

Thu Aug 28, 2014

Merinews

Drug Price Control Order vitiates National Pharma Pricing Policy, needs extensive changes: ASSOCHAM

The expected improvement in availability and affordability of essential medicines as envisaged under the National Pharmaceutical Pricing Policy has been badly vitiated "to a large extent" by the Drug Price Control Order , a study of the pharma industry by the leading business chamber ASSOCHAM has revealed.

Comment?

Medical News

FDA accepts Mylan's ANDA filing for generic Copaxone 40 mg/mL

Mylan Inc. today announced that its abbreviated new drug application for a three times per week Glatiramer Acetate Injection 40 mg/mL has been accepted for filing by the U.S. Food and Drug Administration .

Comment?

Related Topix: Food and Drug Administration, Biotech, Medicine, Mylan Laboratories, Healthcare Industry, Dey, Startups

AmericanBankingNews.com

Raptor Pharmaceutical Corp. Director Unloads $110,100 in Stock

Raptor Pharmaceutical Corp. Director Erich Sager unloaded 10,000 shares of the company's stock on the open market in a transaction that occurred on Monday, August 25th.

Comment?

Related Topix: Raptor Pharmaceuticals

AmericanBankingNews.com

Impax Laboratories Receives Average Recommendation of "Hold" from Analysts

Impax Laboratories has received an average rating of "Hold" from the eighteen brokerages that are presently covering the company, Analyst Ratings Network.com reports .

Comment?

Related Topix: Biotech, Impax Laboratories, Medicine, Healthcare Industry, Startups

HIV and Hepatitis

Achillion NS5A Inhibitor + Sofosbuvir Shows High Early Cure Rate

An interferon-free dual combination of Achillion's hepatitis C virus NS5A inhibitor ACH-3012 plus Gilead Science's HCV polymerase inhibitor sofosbuvir taken for 8 weeks led to sustained virological response at 4 weeks post-treatment for people with HCV genotype 1 in a Phase 2 study, according to a company announcement.

Comment?

Related Topix: Achillion Pharmaceuticals

Business Journal

Mylan CEO on Burger King's potential inversion: 'If this puts sunshine on the issue, that's great'

"We can't sit still and stay in the U.S. because of all the political rhetoric," said Mylan Inc. CEO Heather Bresch, who helped grow the company from $100 million in revenue to $7 billion in about two decades.

Comment?

Related Topix: Mylan Laboratories, Biotech, Medicine, Healthcare Industry

Medical News

Armetheon raises $7 million in first round of financing

Armetheon, Inc. , a biopharmaceutical company focused on developing novel mid- to late-stage cardiovascular drug candidates, today announced that it has raised $7.0 million in its first round of financing.

Comment?

Related Topix: Venture Capital, Emerging Technology, Biotech, Impax Laboratories, Startups, Medicine, Healthcare Industry, Food and Drug Administration, Health

AmericanBankingNews.com

Achillion Pharmaceuticals major shareholder Ra Capital Management, Llc Sells 2,112,867 Shares

Achillion Pharmaceuticals major shareholder Ra Capital Management, Llc sold 2,112,867 shares of Achillion Pharmaceuticals stock on the open market in a transaction dated Tuesday, August 26th.

Comment?

Related Topix: Achillion Pharmaceuticals

Detroit News

The case for drug discounts

It is truly disappointing to see Howard Dean carrying the water for the pharmaceutical industry in his August 6op-ed, ' How drug discounts are being manipulated .'

Comment?

Related Topix: Medicine, Opinion

Wed Aug 27, 2014

Seeking Alpha

Lannett's (LCI) CEO Arthur Bedrosian on 2014 Results - Earnings Call Transcript

Hello, and welcome to the Lannett Company Fiscal 2014 Fourth Quarter and Full Year Financial Results Conference Call.

Comment?

Related Topix: Lannett Company, Biotech, Medicine, Healthcare Industry

Seeking Alpha

Mylan: Deeply Undervalued On Unwarranted Approval Concerns

Mylan is a manufacturer of generic pharmaceuticals. It closed on Tuesday, August 25, 2014 at $48.30.

Comment?

Related Topix: Dey, Biotech, Startups, Medicine, Mylan Laboratories, Healthcare Industry

P&T Community

Teva Recalls - Super Potent' Parkinson's Disease Medication

Teva Pharmaceutical Industries has recalled one lot of its generic Parkinson's disease combination medication carbidopa/levodopa because it may contain too much of an active pharmaceutical ingredient.

Comment?

Related Topix: Biotech, Teva Pharmaceutical Industries, Parkinson's Disease, Health, Medicine, Cephalon, Healthcare Industry

Sys-Con Media

ISPE Releases First Look at its Plan to Prevent Drug Shortages

The Plan, a first for the industry, was developed by ISPE and its expert pharmaceutical and biopharmaceutical industry members and describes how industry can best prevent drug shortages from occurring by discovering root causes and through creating and sustaining organizational cultures supported by leadership, business processes and quality ... (more)

Comment?

Express India

India's Venus Remedies surges; to collaborate with Teva on drug

Venus will collaborate with Teva Pharmaceutical Industries Ltd to develop an anti-cancer drug, it said in a statement on Tuesday.

Comment?

Related Topix: Biotech, Teva Pharmaceutical Industries, Medicine, Healthcare Industry

The Motley Fool

Is It Time to Buy McKesson Corporation Stock?

If you live in North America, there's a one in three chance that a medication you use was distributed by one company -- McKesson Corporation .

Comment?

Related Topix: Biotech, Medicine, McKesson, Household Products, Healthcare Industry, Financial Markets

•••
•••
•••
•••

Pharmaceuticals Jobs

•••
•••
•••
•••